-
-
-
-
-
-
-
Halozyme expects minimal Medicare pricing impact on royalties through 2035
-
-
-
-
-
-
-
TD Cowen Reiterates Top Pick on Halozyme Therapeutics (HALO)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Halozyme Therapeutics (HALO)
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised to $90 at H.C. Wainwright
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) PT Raised to $56 at Goldman Sachs
-
-
-
-
-
-
-
Halozyme Therapeutics (HALO) Announces argenx Received European Commission Approval for VYVGART Subcutaneous Injection with ENHANZE
-
450,069 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

